标题：Co-expression of beta-arrestin1 and NF-(DB)-B-0 is associated with cancer progression and poor prognosis in lung adenocarcinoma
作者：Yu, Jianyu;Wang, Liguang;Zhang, Tiehong;Shen, Hongchang;Dong, Wei;Ni, Yang;Du, Jiajun
作者机构：[Yu, J] Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 2 更多
通讯作者地址：[Du, JJ]Shandong Univ, Shandong Prov Hosp, Dept Thorac Surg, 324 Jingwu Rd, Jinan 250021, Peoples R China.
来源：Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine
关键词：beta-arrestin1;NF-kappa B;p65;Lung adenocarcinoma;Prognosis
摘要：beta-arrestin1 and NF-kappa B have been demonstrated to be associated with tumorigenesis, tumor progression, and metastasis. Thus far, there is nevertheless little study about these two molecules in lung adenocarcinoma. The aim of this study was to investigate the correlation between beta-arrestin1 and NF-kappa B expression and the clinicopathological characteristics in lung adenocarcinoma. A total of 115 surgically resected lung adenocarcinoma patients were recruited for the study. Expression of beta-arrestin1 and p65 were detected by immunohistochemistry (IHC) in lung adenocarcinoma tissue samples. Nuclear expression of beta-arrestin1 and p65 were observed in 39.1 % (45/115) and 46.1 % (53/115) cases of lung adenocarcinoma, respectively. And high expression of beta-arrestin1 had negative prognostic impact for overall survival (OS) and disease-free survival (DFS) (p = 0.034 and p = 0.033). In addition, overexpression of p65 indicated a significantly poor OS and DFS than those of lower-expression (p = 0.038 and p = 0.041). Furthermore, co-expression of nuclear beta-arrestin1 and p65 correlated with poorer OS and DFS in lung adenocarcinoma patients. Multivariate analysis using the Cox regression model confirmed that co-expression of nuclear beta-arrestin1 and p65 was an independent prognostic factor for tumor progression (p = 0.008). In conclusion, these data indicated that co-expression of nuclear beta-arrestin1 and p65 was a novel predictor for worse prognosis in patients with lung adenocarcinoma.